UPDATED: Verastem shares crater on Twitter chatter around cancer data

John Carroll

of cratered Wednesday morning as the crowd passed an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response rate for KRAS mutant non-small cell lung .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS